PLUR News & Events

Pluri announces that the China National Intellectual Property Administration, CNIPA, has granted Pluri Biotech, a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and activation technology. The patent, titled "System and Methods for Immune Cells Expansion and Activation in Large Scale," expands Pluri's global intellectual property portfolio, including granted patents in the United States and additional granted patents in Japan, Korea, Australia and Israel. The expanded portfolio supports the Company's strategy to pursue global collaboration and licensing agreements for immune cell therapy products built on Pluri's automated, large-scale manufacturing platform.

Pluri announced the completion of the first phase of its program with Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO. Under the program, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to support Resbiomed in establishing protocols for tissue extraction, separation and processing designed to preserve, concentrate and enhance endogenous collagen components and yield high-quality biological materials for diverse regenerative-medicine applications.

Pluri announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell's personnel, along with Pluri's Contract Development and Manufacturing Organization division, have successfully completed the full implementation of Remedy Cell's proprietary manufacturing process into Pluri's Good Manufacturing Practice, GMP, facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell's lead candidate. These batches are intended for use in Remedy Cell's initial Phase 1b clinical trial, representing a major step in its clinical development

Pluri announced that Alejandro Weinstein, one of the Company's largest shareholders, has been appointed Chairman of the Board of Directors. The company said the "appointment reflects the Board's view that Weinstein brings a decisive, business driven perspective that aligns with Pluri's objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company's underlying assets."